KAITLYN GEISS: Open Payments
NPI 1881174324 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$994 in 49 payments from 12 companies in 2025. Trend: 2023 $1,281 · 2024 $1,307 · 2025 $994
Food & beverage: $994
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 10 | $201 |
| ABBVIE INC. | 11 | $173 |
| GENZYME CORPORATION | 3 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $98 |
| Gilead Sciences, Inc. | 5 | $84 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $84 |
| Lilly USA, LLC | 3 | $73 |
| Ardelyx, Inc. | 3 | $62 |
| Regeneron Healthcare Solutions, Inc. | 2 | $53 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
Products named: TREMFYA, DUPIXENT, RINVOQ, ENTYVIO, XIFAXAN, OMVOH, IBSRELA, MAVYRET.
Industry payments across IN — which companies pay providers there.
